Cogent reports Q3 2026 results, three bezuclastinib PDUFA dates aheadNov 5Quarterly updatebezuclastinibCogent Biosciences, Inc.
FDA approves efficacy supplement for Blueprint Medicines' AyvakitOct 16Regulatory decisionavapritinib
Cogent Biosciences reports Q2 2026 results, two bezuclastinib PDUFA dates aheadAug 10Quarterly updatebezuclastinibCogent Biosciences, Inc.